The agreement grants to EWA Government Systems (EWA GSI) the right to market both the gel and powder forms of CellerateRx and will be compensated strictly on a commission basis for products sold.
CellerateRx patented collagen fragments (CRX) are a fraction of the size of native collagen molecules found in other products, and provide the benefits of collagen to the body immediately.
Scott Haire, CEO of Wound Management Technologies, said: “We believe that this agreement is a huge step for us, and that EWA GSI’s capabilities in marketing our product represent a strong alliance with a major distributor that facilitates the needs of government entities.”